The peroxisome proliferator-activated receptor-g (PPAR-g) is a nuclear receptor that is activated by lipids to induce the expression of genes involved in lipid and glucose metabolism, thereby converting nutritional signals into metabolic consequences 1 . PPAR-g is the target of the thiazolidinedione (TZD) class of insulin-sensitizing drugs, which have been widely prescribed to treat type 2 diabetes mellitus. A common side effect of treatment with TZDs is weight gain 2 . Here we report a previously unknown role for central nervous system (CNS) PPAR-g in the regulation of energy balance. We found that both acute and chronic activation of CNS PPAR-g, by either TZDs or hypothalamic overexpression of a fusion protein consisting of PPAR-g and the viral transcriptional activator VP16 (VP16-PPAR-g), led to positive energy balance in rats. Blocking the endogenous activation of CNS PPAR-g with pharmacological antagonists or reducing its expression with shRNA led to negative energy balance, restored leptin sensitivity in high-fat-diet (HFD)-fed rats and blocked the hyperphagic response to oral TZD treatment. These findings have implications for the widespread clinical use of TZD drugs and for understanding the etiology of diet-induced obesity.
Despite intense investigation, PPAR-γ remains an orphan nuclear receptor; that is, a high-affinity endogenous ligand has not yet been identified. Rather, several dietary fats and their metabolites bind PPAR-γ, but with moderate affinity, leading to the suggestion that the physiological role of PPAR-γ is to act as a sensor for the integrated flux of multiple fatty acids 1 . Consistent with this possibility, PPAR-γ is highly expressed in white adipose tissue (WAT), where it is a key regulator of adipogenesis 3, 4 and where PPAR-γ activation promotes increased lipid storage 5, 6 . Chronic peripheral administration of exogenous PPAR-γ agonists, including the TZD rosiglitazone, improves glycemic control at the expense of increased caloric intake, body weight and body fat gain 2, 7, 8 . Chronic peripheral administration of PPAR-γ antagonists also confers protection from dietinduced obesity 9 .
The traditional view has been that these changes in energy balance are mediated primarily by the actions of PPAR-γ to induce adipogenesis in WAT. However, we would emphasize the point made elsewhere 10 that simply "having more fat cells does not make an animal fatter. In the absence of altered energy balance, an increase in adipogenesis will result in smaller fat cells with no change in total adiposity." Pertinent to this, PPAR-γ is also expressed in regions of the hypothalamus involved in the central regulation of energy balance [11] [12] [13] . We therefore hypothesized that activation of CNS PPAR-γ by rosiglitazone contributes to its effect on energy balance and that activation of CNS PPAR-γ by its endogenous lipid agonists provides a direct mechanism underlying HFD-induced hyperphagia and leptin resistance.
To test the notion that direct activation of CNS PPAR-γ by rosiglitazone would result in positive energy balance, we administered small doses of the drug or its vehicle (25% vol/vol DMSO) into the third cerebral ventricle (i3vt) of male Long-Evans rats in the area of the ventral hypothalamus. Acute i3vt rosiglitazone resulted in a 50% higher caloric intake over 24 h, with a corresponding higher body weight change compared to i3vt vehicle alone ( Fig. 1a,b ). Furthermore, a single bolus of i3vt rosiglitazone led to significantly greater food intake for as many as 3 d (Fig. 1c) , and body fat gain was still higher 7 d after the single injection ( Fig. 1d ) compared to i3vt vehicle alone. We found no differences in chow intake after an oral dose of rosiglitazone (0 versus 0.1 mg per kg body weight) roughly 30 times greater than the dose given by i3vt (vehicle: 26.34 ± 0.58 g, rosiglitazone: 27.64 ± 0.71 g), ruling out that our i3vt treatments had peripheral orexigenic effects.
To determine whether rosiglitazone could activate neuronal populations involved in the regulation of energy balance, we measured immunoreactivity of c-Fos, a marker of neuronal activity, in rat hypothalamus 1 h after an acute i3vt injection of rosiglitazone. There was a significantly greater induction of c-Fos in the paraventricular ( Fig. 1e,f) , but not in the arcuate or dorsomedial, nucleus of the hypothalamus (Supplementary Fig. 1a,b ) among rats injected with rosiglitazone compared to those injected with vehicle alone.
Fusion of the viral transcriptional activator VP16 to PPAR-γ potently and constitutively activates PPAR-γ in the absence of ligand 14 and has been used to explore the effects of chronic tissue-specific PPAR-γ activation 15, 16 . Thus, to investigate the effects of chronic activation of CNS PPAR-γ, we used a lentiviral vector to overexpress VP16-PPAR-γ locally in the hypothalamus of male rats ( Supplementary Fig. 2a,b) . Over the course of 4 weeks after the lentivirus infusions, rats that had received the VP16-PPAR-γ virus consumed more calories, gained more weight and gained twice as much body fat as control-treated rats ( Fig. 1g-i) . Collectively, these data suggest a potential role for hypothalamic PPAR-γ in both acute and chronic regulation of food intake and adiposity.
These findings additionally suggest that peripheral administration of TZD drugs might increase weight gain by activating CNS PPAR-γ. To test this hypothesis explicitly, we administered rosiglitazone or its vehicle via oral gavage and simultaneously infused the PPAR-γ antagonist GW9662 or its vehicle (33% vol/vol DMSO) i3vt. It is well established that treatment with oral TZDs over the course of weeks or months induces weight gain in humans 8, 17 and in rodents 2, 18 . We observed that a single oral dose of rosiglitazone induced hyperphagia and greater body weight gain within 24 h ( Fig. 2a,b ) compared to vehicle alone. To rule out that this weight gain was associated with greater plasma volume 19 , we measured hematocrits from rats following oral rosiglitazone or its vehicle ( Fig. 2c,d) . Furthermore, when we blocked CNS PPAR-γ receptors by administering 1 µg of GW9662 i3vt, the acute orexigenic effect of oral rosiglitazone was completely attenuated ( Fig. 2e) . To test the hypothesis in another way, we administered an shRNA against PPAR-γ locally into the hypothalamus using a lentiviral vector ( Supplementary Fig. 3 ). Acute oral rosiglitazone again elicited greater food intake, compared to vehicle, among rats that had received the scrambled control shRNA, but this effect was blunted in rats receiving the shRNA against PPAR-γ ( Fig. 2f) . These data suggest that peripheral administration of TZDs results in activation of hypothalamic PPAR-γ that can drive higher food intake.
Consistent with these findings, two groups have reported that a modest amount of systemically delivered rosiglitazone crosses the bloodbrain barrier 18, 20 . However, those groups drew opposing conclusions regarding the implications of their findings. One study concluded that the modest levels of rosiglitazone found in whole mouse brain after intravenous administration were insufficient to account for the blunted thyroid status and sympathetic tone observed after peripheral rosiglitazone administration 18 . This conclusion was based primarily on the failure to observe any changes in energy balance after a 14-d continuous intracerebroventricular (i.c.v.) infusion of rosiglitazone via osmotic pump in a small number of rats (n = 4 per group). The discrepancy between these findings and ours might be explained if rosiglitazone were unstable in an aqueous solution at body temperature over this time frame. Alternatively, they may result from other differences in experimental design. Conversely, another study 20 concluded that the modest levels of rosiglitazone present in mouse cortex after oral delivery of a therapeutic dose (a comparable dose to ours, 10 mg per kg body weight per day) exceeded the half-maximal effective concentration for rosiglitazone at PPAR-γ and could account directly for changes they observed in the CNS after an oral dose.
Next we investigated whether hypothalamic PPAR-γ has a physiologically important role, as blocking its endogenous activation locally within the CNS should lead to negative energy balance. We found that fasted, but not ad libitum-fed, rats maintained on a lowfat chow diet and treated with acute i3vt GW9662 had lower 24-h food intake compared to those treated with vehicle alone (Fig. 3a,b) . When GW9662 or its vehicle was administered i3vt to HFD-induced obese rats and their age-matched chow-fed controls, the antagonisttreated HFD-fed rats consumed 40% fewer calories compared to vehicle controls, but the same dose had no effect in the chow-fed rats (Fig. 3c) . This difference in caloric intake was reflected by a lower body weight change in HFD-fed, but not chow-fed, rats (Fig. 3d) . Consistent with this, a previous study 12 reported that neuron-specific PPAR-γ-knockout mice show no metabolic phenotype when maintained on a standard chow diet, though no data were presented from HFD-fed mice. Together, the data from this previous study and our current study suggest that the physiological role of CNS PPAR-γ is greater during fasting or in rats fed a HFD, with both physiological states characterized by an increased flux of fatty acids.
Notably, we also found that the plasma thyroid-stimulating hormone concentration was more than fivefold higher among dietinduced obese rats acutely treated with i3vt GW9662 compared to those treated with vehicle alone (Supplementary Fig. 4a ). These data agree with previous reports of cross-talk between PPAR-γ and the hypothalamic-pituitary-thyroid (HPT) axis 21, 22 . Moreover, they are consistent with the reduced thyroid status previously observed among adult rats after oral rosiglitazone administration 18 , and they fit with an overall catabolic effect of the antagonist. In contrast, a recent study reported that rosiglitazone increases thyroid status in newborn mice 22 , suggesting that development may be a crucial factor modulating this interaction. We did not observe differences in thyrotropin-releasing hormone (Trh) mRNA levels (Supplementary Fig. 4) , and there was a trend toward higher plasma tri-iodothyronine concentration (Supplementary Fig. 4b) .
Given the relative sluggishness of the HPT axis, we suspect that tri-iodothyronine had not yet reached its peak response to increased thyroid-stimulating hormone at this time point. Thus the role of the HPT axis to mediate effects of CNS PPAR-γ signaling must therefore remain speculative and is a priority for future research.
A hallmark of HFD-induced obesity is leptin resistance. Leptin is a peptide hormone secreted by WAT in proportion to total adiposity, thereby providing an indicator of the levels of stored energy in adipose tissue 23 . Leptin activates its receptors in various hypothalamic nuclei; its downstream effectors are integrated in the paraventricular nucleus of the hypothalamus, where Trh is also expressed 24 . Leptin's actions in the hypothalamus and in other areas of the CNS reduce food intake and deplete energy storage in WAT 25 . Leptin signaling in the hypothalamus is blunted in rats fed a HFD 26 , and this leptin resistance is thought to contribute to the continued accumulation of body fat. Because the endogenous ligands of PPAR-γ are thought to be fatty acids, and given the results of our previous experiments, we hypothesized that hypothalamic PPAR-γ may contribute to the development of HFD-induced leptin resistance. We predicted that chronic antagonism of CNS PPAR-γ with GW9662 would restore leptin sensitivity in HFD-fed leptin-resistant rats. To test this, we chronically delivered GW9662 or its vehicle into the lateral ventricle of HFD-fed rats, using a subthreshold dose that has no effect on body weight (Fig. 4a) but that results in significantly lower hypothalamic expression of the PPAR-γ target gene lipoprotein lipase (Lpl) (Fig. 4b) .
After 14 d, we challenged these rats with exogenous intraperitoneal (i.p.) leptin at a dose that reduces caloric intake and body weight 27 and induces hypothalamic c-Fos 28 in lean rats. Rats concurrently receiving i.c.v. GW9662 and i.p. leptin had lower 24-h food intake ( Fig. 4c ) and body weight change (Fig. 4d) compared to those receiving i.c.v. GW9662 and i.p. vehicle, whereas the weight-matched vehicle-treated rats remained leptin resistant. These findings implicate PPAR-γ as a potential molecular link between fatty acids and leptin action to regulate food intake.
Our data collectively reveal a previously unknown role of hypothalamic PPAR-γ in the central regulation of energy balance, and they imply that CNS mechanisms may underlie at least some of the weight gain observed with PPAR-γ-modulating drugs. In further support of this possibility, it was recently reported that constitutive PPAR-γ activation specifically in adipocytes improves the glucose tolerance of DIO mice but does not lead to increased weight gain 15 . An additional implication, therefore, is that differential access to the CNS by different PPAR-γ ligands and their formulations may result in different therapeutic outcomes. Notably, these data also identify a physiological pathway by which increased consumption of lipids can promote leptin resistance and obesity via hypothalamic PPAR-γ.
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Rats. The Institutional Animal Care and Use Committee at the University of Cincinnati approved all rat protocols. We housed adult male Long-Evans rats (Harlan) individually in plastic tub cages and maintained them on a 12-h-12-h light-dark cycle with ad libitum access to water and pelleted rodent chow (Harlan Teklad) or pelleted 40% butter-fat diet (Research Diets) unless otherwise noted.
Intracerebroventricular cannulations.
For i3vt studies, we outfitted rats with a cannula (Plastics One) directed toward the third cerebral ventricle and confirmed correct placement as previously described 29 . For chronic i.c.v. studies, we outfitted rats with brain infusion kits (Alzet) into the lateral cerebral ventricle and connected to subcutaneously implanted osmotic pumps (model 2006, Alzet) with polyethylene tubing, according to the manufacturer's instructions as previously described 30 .
Drugs. For central studies, we dissolved rosiglitazone (Cayman Chemicals) in 25% DMSO and injected it i3vt in a volume of 2 µl. For peripheral studies we suspended rosiglitazone in 0.5% methyl cellulose and administered it by oral gavage in a volume of about 4 ml. We dissolved GW9662 (Cayman Chemicals) in 33% DMSO and injected it i3vt in a volume of 2 µl. We dissolved leptin (PepProTech) in water and injected it i.p. in a volume of about 0.5 ml.
Food intake and body composition studies. We removed food 6 h before the onset of dark and assigned rats to weight-matched groups. We administered rosiglitazone, GW9662 or leptin beginning 3 h before the onset of dark. We returned food at lights out and recorded food and body weight at selected time points. We measured body composition in triplicate by Echo magnetic resonance imaging. c-Fos immunohistochemistry. We pretreated weight-matched rats with i3vt rosiglitazone (1 µg) or vehicle. One hour later, they were deeply anesthetized with sodium pentobarbital and perfused transcardially with 0.9% wt/vol saline followed by 4.0% wt/vol paraformaldehyde in sodium phosphate. We postfixed brains at 4 °C for 24 h in 4.0% wt/vol paraformaldehyde in sodium phosphate and stored them at 4 °C in 30.0% wt/vol sucrose-PBS.
We identified c-Fos-positive cells by chromagen immunhistochemistry. We collected coronal hypothalamic sections (35 µm) in 1:3 series using a freezing microtome. We stored sections in ethylene glycol cryoprotectant at −20 °C until time of use. Briefly, we removed tissue sections from cryoprotectant and washed them in 0.1 M PBS. To block endogenous peroxidases, tissue was soaked in 9:1 methanol:3% hydrogen peroxide solution for 15 min and subsequently rinsed in PBS. We then preincubated tissue in blocking buffer (PBS plus 0.4% Triton X-100 plus 2% normal donkey serum) for 30 min at 21 °C, followed by incubation with c-Fos-specific antibody (1 in 2,500, Santa Cruz Biotechnology sc-52) in blocking buffer for 48 h at 4 °C. After washing in PBS, we incubated tissue for 1 h in a solution containing biotinylated donkey rabbit-specific antibody (1 in 300, Vector Laboratories BA-1000) and subsequently washed and incubated tissue in avidin-biotin solution (1 in 600, Vector Laboratories PK-6100) for 30 min. We visualized c-Fos immunoreactivity with 3,3′-diaminobenzidine-enhanced with nickel chloride.
We used The Rat Brain Atlas by Paxinos to match hypothalamic levels −1.3 to −3.30 mm caudal to bregma. Using a Zeiss Axioplan 2 Microscope coupled with a Zeiss Axiocam camera, we obtained adjacent images of c-Fos at 5× using Axiovision 4.8 Software. Using Scion Image 4.0.3.2., we uploaded images and subtracted the background. We optimized each density slice for positive staining and counted positive cells in the paraventricular, arcuate and dorsomedial nuclei of the hypothalamus. We averaged the number of c-Fos-positive cells across each nucleus. An individual blinded to the experimental treatment groups scored the sections.
In vivo VP16-PPAR-g studies. The Institutional Biosafety Committee at the University of Cincinnati approved all lentivirus protocols.
America Pharma Source concentrated the viruses to 1 × 10 8 viral units per µl. Briefly, we used a Hamilton syringe mounted to the stereotaxic apparatus (KOPF) to directly infuse 2 µl of concentrated virus bilaterally into the medial hypothalamus (-2.2 mm from bregma, −8.5 mm from dura, ± 0.6 mm lateral of midline) of standard chow-fed rats under ketamine-xylazine anesthesia. We infused virus over 20 min, allowed the Hamilton syringe to rest for an additional 10 min and then slowly withdrew it. A single dose of buprenorphine (Reckitt Benckiser Healthcare), 0.3 mg per kg body weight, was given for analgesia at the time of the surgery.
In vivo shRNA studies. America Pharma Source concentrated the viruses to 1 × 10 9 viral units per µl. Briefly, we outfitted rats under isoflurane anesthesia with bilateral cannulas (Plastics One) directed into the medial hypothalamus (-2.2 mm from bregma, −7.5 mm from dura, ± 0.6 mm lateral of midline). We lowered an injector projecting 1 mm below each cannula and infused 2 µl of concentrated virus bilaterally over 20 min. We allowed the injector to rest for an additional 10 min and then slowly withdrew the cannula and injector. A single dose of buprenorphine (Reckitt Benckiser Healthcare), 0.3 mg per kg body weight, was given for analgesia at the time of the surgery. Rats recovered for 2 weeks before challenge with oral rosiglitazone.
Statistical analyses.
All values are reported as means ± s.e.m. We analyzed the data using Student's t test, Mann-Whitney, Kruskal-Wallis or ANOVA. We made post hoc multiple comparisons using Tukey's or Dunn's post hoc tests. Significance was set at P < 0.05 for all analyses. 
